Evaluation of thiamine as adjunctive therapy in COVID-19 critically ill patients: a two-center propensity score matched study

Autor: Aisha Alharbi, Abdulkareem M. Al Bekairy, Shmeylan Al Harbi, Ramesh Vishwakarma, Rahmah Algarni, Mashael Al Muqrin, Ohoud Aljuhani, Maram Al Dossari, Fahad A. Al Eidan, Nouf Al Qahtani, Abdulmalik Al Katheri, Asma M. Alshahrani, Majed Al Jeraisy, Khalid Al Sulaiman, Ghassan Al Ghamdi
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Adult
Male
medicine.medical_specialty
Coronavirus disease 2019 (COVID-19)
Critical Illness
30-day mortality
Pneumonia
Viral
Critical Care and Intensive Care Medicine
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Risk Factors
Intensive care
Internal medicine
medicine
Intensive care units (ICUs)
Humans
030212 general & internal medicine
Thiamine
Hospital Mortality
Critically ill
Propensity Score
Retrospective Studies
business.industry
RC86-88.9
SARS-CoV-2
Research
COVID-19
030208 emergency & critical care medicine
Retrospective cohort study
Medical emergencies. Critical care. Intensive care. First aid
Thrombosis
Vitamins
medicine.disease
COVID-19 Drug Treatment
Intensive Care Units
chemistry
Propensity score matching
Female
business
Thiamine pyrophosphate
Vitamin B1
Zdroj: Critical Care
Critical Care, Vol 25, Iss 1, Pp 1-8 (2021)
ISSN: 1466-609X
1364-8535
Popis: Background Thiamine is a precursor of the essential coenzyme thiamine pyrophosphate required for glucose metabolism; it improves the immune system function and has shown to reduce the risk of several diseases. The role of thiamine in critically ill septic patient has been addressed in multiple studies; however, it’s role in COVID-19 patients is still unclear. The aim of this study was to evaluate the use of thiamine as an adjunctive therapy on mortality in COVID-19 critically ill patients. Methods This is a two-center, non-interventional, retrospective cohort study for critically ill patients admitted to intensive care units (ICUs) with a confirmed diagnosis of COVID19. All patients aged 18 years or older admitted to ICUs between March 1, 2020, and December 31, 2020, with positive PCR COVID-19 were eligible for inclusion. We investigated thiamine use as an adjunctive therapy on the clinical outcomes in critically ill COVID-19 patients after propensity score matching. Results A total of 738 critically ill patients with COVID-19 who had been admitted to ICUs were included in the study. Among 166 patients matched using the propensity score method, 83 had received thiamine as adjunctive therapy. There was significant association between thiamine use with in-hospital mortality (OR = 0.39; 95% CI 0.19–0.78; P value = 0.008) as well as the 30-day mortality (OR = 0.37; 95% CI 0.18–0.78; P value = 0.009). Moreover, patients who received thiamine as an adjunctive therapy were less likely to have thrombosis during ICU stay [OR (95% CI) 0.19 (0.04–0.88), P value = 0.03]. Conclusion Thiamine use as adjunctive therapy may have potential survival benefits in critically ill patients with COVID-19. Additionally, it was associated with a lower incidence of thrombosis. Further interventional studies are required to confirm these findings.
Databáze: OpenAIRE
Externí odkaz: